The conundrum Do you have a link / reference ?
The conundrum Interesting burst of buying interest today pushing the sp a little further north TP
The conundrum Yep, I think there really is nothing to add until we get those results on phase 3. It totally depends on getting good phase 3 results. By that I mean clinical relevant scores being achieved with statistical significance for mild and mild to moderate group of patients. If we could get the moderate group too, that would be the icing on the cake for me. Not too bothered about the severe cases as they tend to bring in lower amounts of sale volumes (less frequent action!, maybe once or twice a month if they’re lucky) We really need to get the mild, mild to moderate and moderates… These are the groups that will drive the sales for any company purchasing the asset.
The conundrum I honesty expect an update on cashburn due to P3, (Negative) Then they will just repeat all is running well and expected TRP late summer and P3 still on track. This is really a wait game until Q4’18.
The conundrum The results are for the full year so we should see more detail. It’s a simple waiting game regarding MED so I’m not expecting any news there. But I’m hoping for a good update on TPR. I still think the new trademark “Dermamax” applied for by Thornton & Ross relates to TPR and the application has recently been published ………. [link] ……… so we’re about a couple of months off registration. And I still think the application was due to positive responses from the MHRA which may be touched upon in the results. If so, this could have a significant positive impact in that it shows Thornton & Ross’s commitment (unlike previous partnerships) and could pave the way for a decent milestone payment on approval and also the possibility of further regional deals for TPR with Thornton & Ross a likely candidate given their commitment to the UK deal. In turn this could solve any part 2 Phase 3 MED funding issues but I think positive part 1 results will see MED (or FUM as a whole) being sold anyway.
The conundrum What are we expecting from mid year results then any ideas? I would imagine updates on clinical trials and possible tpr update? Hoping this crosses the 20p mark but seems stuck at 15p
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster What happens next? in 20 days coming the news !
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster Futura Medical – Exciting milestone approaches… By Mark Watson-Mitchell 14 March 2019 [link]
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster I wouldn’t expect anything to come on results apart from a repeat of any positives they did in the last 6 months + updated cash burn. TRP end of Q2, probably nothing until then.
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster When does the rally start? The Mcap is low. News are comming. We wait for the 10. April for Preresults. TPR100 (Topical Gel for Pain ) first approval expected next Quarter. Everything is manageable. Nevertheless the stock Price is at 15p. it must be at 40p.
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster Yes & yes is the answer to that lol. Although i hold 147,641 shares at 14.9p, Hoping this drops back as i have a 15k order at 12.8p. Long term before results 27p easily
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster And do you repeatedly post the same long winded cut and post comments on there?
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster Notice of Preliminary Results 05 March 2019 Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, will announce its preliminary results for the year ended 31 December 2018 on Wednesday 10 April 2019. James Barder, Chief Executive Officer, and Angela Hildreth, Finance Director/Chief Operating Officer, will host a presentation for analysts at 10am BST on the day of the results at the office of N+1 Singer at 1 Bartholomew Lane, London EC2N 2AX. A copy of the announcement will be made available on the Futura Medical website and following the results meeting a webcast of the presentation to analysts will also be made available within the Investor Centre section of the site. For further information please contact: Futura Medical plc James Barder, Chief Executive Angela Hildreth, Finance Director and COO Email: Investor.firstname.lastname@example.org Tel: +44 (0) 1483 685 670 Nominated Adviser and Broker: N+1 Singer Aubrey Powell/ Ben Farrow (Corporate Finance) Mia Gardner / Tom Salvesen (Corporate Broking) Tel: +44 (0) 20 7496 3000 For media enquiries please contact: Optimum Strategic Communications Mary Clark/ Hollie Vile/ Ellie Blackwell Email: email@example.com Tel: +44 (0) 203 950 9144 Notes to editors: About Futura Medical plc Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster yes have an account there
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster Are you bioking on ADVFN?